Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Carcinoma, Renal Cell 4Recurrence 1Prostatic Hyperplasia 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × TroVax × Clear all
NCT00397345 2020-10-19

TroVax Renal Immunotherapy Survival Trial

Oxford BioMedica

Phase 3 Completed
733 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡